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Abstract
Background: There is a recognised need to build primary care medication adherence services which are tailored
to patients’ needs. Continuous quality improvement of such services requires a regular working method of
measuring adherence in order to monitor effectiveness. Self report has been considered the method of choice for
clinical use; it is cheap, relatively unobtrusive and able to distinguish between intentional and unintentional non-
adherence, which have different underlying causes and therefore require different interventions. A self report
adherence measure used in routine clinical practice would ideally be brief, acceptable to patients, valid, reliable,
have the ability to distinguish between different types of non-adherence and be able to be completed by or in
conjunction with carers where necessary.
Methods: We systematically reviewed the literature in order to identify self report adherence measures currently
available which are suitable for primary care and evaluate the extent to which they met the criteria described
above. We searched the databases Medline, Embase, International Pharmaceutical Abstracts, Pharmline, CINAHL,
PsycINFO and HaPI to identify studies reporting the development, validation or reliability of generic adherence
measures. One reviewer screened all abstracts and assessed all relevant full text articles obtained and a second
reviewer screened/assessed 10% to check reliability.
Results: Fifty eight measures were identified. While validation data were presented in support of the vast majority
of self reported measures (54/58), data for a relatively small number of measures was presented for reliability (16/
58) and time to complete (3/58). Few were designed to have the ability to be completed by or in conjunction
with carers and few were able to distinguish between different types of non-adherence, which limited their ability
be used effectively in the continuous improvement of targeted adherence enhancing interventions. The data
available suggested that patients find it easier to estimate general adherence than to report a specific number of
doses missed. Visual analogue scales can be easier for patients than other types of scale but are not suitable for
telephone administration.
Conclusions: There is a need for a measure which can be used in the routine continual quality monitoring of
adherence services.
Background
There is a need to build informed, comprehensive, pri-
mary care-based medication adherence services which
are tailored to patients’ needs [1]. Non-adherence to
medication is estimated to affect approximately 30-50%
of patients with chronic conditions [2]. The
consequences include a missed opportunity for treat-
ment effect, poor health outcomes and increased health-
care costs. For example, it has been estimated that non-
adherence is responsible for 48% of asthma deaths, an
80% increased risk of death in diabetes and a 3.8-fold
increased risk of death in the year following a heart
attack [3]. In the United Kingdom National Health Ser-
vice (NHS), medicines are the biggest expenditure after
staff and 71% of the medication budget is spent in pri-
mary care. It is estimated that the current cost of
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unused or unwanted medicines exceeds £300 million
annually [4]. A recent paper that mapped the quality of
medicines use in primary care estimated that only
between four and 21% of patients achieve effective, error
free care, and that an improvement in adherence would
be the most significant area to target to improve medi-
cine use [5].
If one is to improve some aspect of a service or beha-
viour it is generally accepted that there needs to be
some measure associated with the behaviour, which can
be used to assess the success of interventions. All the
various managerial continuous improvement processes
depend on having key measures which can be taken
repeatedly as an indicator of the success of improve-
ment strategies. Improving adherence should be no dif-
ferent. In order to build effective targeted adherence
services, a simple, valid and reliable method for detect-
ing the prevalence and type of non-adherence to medi-
cines is needed [6]. It is important to be able to monitor
the extent of adherence in individual patients and popu-
lations as part of routine clinical practice. There is a
requirement for a method with which non-adherence
can be assessed in individuals, appropriate interventions
instigated, and the effectiveness of the intervention eval-
uated. In order to continually improve quality of services
provided to a population, there is a need to have a regu-
lar working method to monitor the effectiveness of the
service and for pharmacists and Primary Care Trusts
(local state funded primary care management organisa-
tions) to evaluate the effectiveness of changes to the ser-
vice. In adherence-related services, improvements in
adherence of the population using the service is an
important marker of quality. In order to monitor adher-
ence, understand the reasons for non-adherence and
improve the effectiveness of adherence services there is
a need for frequent, regular measurements which are
not very time consuming to make.
As it is not possible to measure actual adherence
without continually observing patients, the measures
that are used may be considered as proxy measures of
adherence rather than absolute measures of adherence.
Methods that have been used include using a container
that has an electronic chip in the lid that records the
time of each opening (Medication Event Monitoring
System- MEMS), pill counts, pharmacological and bio-
chemical markers, medical and dispensing records and
self report. Each of these measures assesses a different
stage in the prescribing and use of medicines, and a dif-
ferent time period. Thus medical records measure the
amount of medication prescribed, dispensing records
the amount of medication dispensed, MEMS measures
the opening of the container, pill counts measure the
amount of medication removed from the container,
pharmacological markers give an indication of when and
how much medication the patient has ingested and self
report measures the patients’ recall of what they have
taken. Medication prescribed, dispensed, the opening or
emptying of containers or report that medication has
been taken do not necessarily reflect what the patient
has taken and therefore may be considered as measures
of variables indicative of adherence rather than absolute
measures of medication use. However, they are
described as adherence measures in the literature, and
are described as such in this review for consistency.
Therefore rather than there being a ‘gold standard’,
the choice of measure will depend on the specific situa-
tion. Many of the measures used in research have lim-
ited feasibility for use in clinical practice. For example,
accurate pharmacological measures are only available
for a limited number of medications and are intrusive
and costly. They may therefore be useful when measur-
ing adherence of a specific medication for which there is
a pharmacological indicator to enable change during the
intervention to be assessed and when there is a limit to
the number of times adherence needs to be measured.
MEMS is also very expensive relative to the costs of
many medicines used in primary care and is not suitable
for all formulations and medications. It may be more
useful for a single solid dosage medication being deliv-
ered and monitored as part of a clinical trial than multi-
ple drug use in routine primary care. Medical records,
dispensing records and pill counts may assist with build-
ing a picture of patients’ adherence over time but will
not be able to assess adherence at a more specific point
in time and may not be as useful for continuous routine
monitoring.
Self report may be considered the most appropriate
method to use for monitoring adherence as part of con-
tinuous quality improvement in clinical practice. Self
report has its disadvantages as patients are known to
overestimate their level of adherence [6]. For this reason
in research studies self report is triangulated with other
methods of measuring adherence [6]. However, NICE
guidelines have identified that whilst other types of mea-
sures are useful for clinical trials of new drugs, self
report is an appropriate tool for clinical practice [7].
Triangulating between methods would not be practical
for regular clinical use. In clinical practice we need to
measure adherence in a cheap and relatively unobtrusive
way which can be used routinely. We also need to dis-
tinguish between intentional and unintentional non-
adherence, which have different underlying causes and
therefore require different interventions. Self report is
the only measure which is able to meet all these criteria.
Recent reviews have shown that self report has moder-
ate correlation with electronic monitoring [8,9],
although self reported adherence levels are higher than
adherence levels derived from MEMS [9].
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A self report measure, which can be used for the con-
tinuous quality improvement of adherence related ser-
vices, needs to have optimal pragmatic, psychometric
and theoretical properties.
Pragmatic properties
The measure must be low cost, brief and non intrusive
so that it can be used to take repeated measures of self
reported adherence over time. It would be preferable for
the measure to be able to be administered in different
ways, for example, by telephone, face to face and by
post. It would also be advantageous if the measure was
suitable for both patient self administration and for
administration by an interviewer. Questionnaires have
been found to have better correlation with other mea-
sures than interviews [10] but some patients may
require assistance, so flexibility in method of administra-
tion is important. In primary care patients are often
treated for multiple conditions. Therefore a measure for
a primary care adherence service needs to be generic
rather than disease specific and should be suitable for
patients taking a single medication or multiple medica-
tions for different conditions. It is important to include
information from carers where appropriate as it is
acknowledged they can have significant roles in medica-
tion management [11].
Psychometric properties
Validity (a check that the instrument is measuring what
it is supposed to measure) should be established. In
adherence research, this is often done by checking the
measure against other measures of adherence such as
MEMS, Pill counts and clinical markers). Reliability (the
consistency of the measurement score) and acceptability
to respondent are required. The measure must also be
sensitive enough to measure change.
Theoretical properties
The measure also needs to have a theoretical basis that
reflects the need for patient tailored adherence services.
The accident causation framework can be used to estab-
lish the underlying contextual and individual factors
contributing to non-adherence [12]. Thus adherence can
be seen as a ‘symptom’ rather than a ‘diagnosis’. In
order to target adherence services to support patients’
needs, it is necessary to establish the causes of non-
adherence. In particular we need to be able to distin-
guish between intentional and unintentional non-adher-
ence, as they have different underlying causes and
therefore require different interventions. In the past,
explanatory psychological models (such as the social
cognition theories [13] and the stages of change model
[14]) have been used to identify beliefs and attitudes
that are predictive of non-adherence. However, models
focussing on beliefs can only explain intentional beha-
viour, whilst unintentional causes of non-adherence are
left unexplained. Therefore, such models are not suitable
for the development of self report measures that are
able to diagnose the extent and full range of reasons for
non-adherence, in individual patients and populations.
The accident causation framework is the only model
that we have found that has incorporated unintentional
non-adherence.
In this paper, we aim to systematically review the lit-
erature in order to identify the self report adherence
measures currently available which are suitable for gen-
eric use and evaluate the extent to which they meet the
theoretical, pragmatic and psychometric criteria
described above.
Methods
Search strategy
We carried out a systematic review of studies addressing
the development, validation and reliability of self
reported adherence measures, searching the following
databases: Medline (1948-July 2010), EMBASE (1980-
July 2010), International Pharmaceutical Abstracts
(1970-July 2010), Pharmline (1978-July 2010), CINAHL
(1982-July 2010), PsycINFO (1806-July 2010) and HaPI
(1985-July 2010). We used the keywords(complian * OR
adheren*) AND (measure* OR scale* OR questionnaire*)
AND (self AND report* OR self-report*) AND (valid*
OR develop*). We also searched the reference lists of
relevant papers in order to identify any additional stu-
dies and contacted known experts.
Inclusion and exclusion criteria
Inclusion Criteria
Studies that report development, reliability or validation
of a retrospective self report adherence measure against
a non-questionnaire measure (such as MEMS, pill
counts and clinical markers).
Exclusion Criteria
• Studies not published in English.
• Studies reporting development or validation of a
questionnaire written in a language other than
English.
• Studies reporting development or validation of a
questionnaire where the full wording of the ques-
tionnaire is not available (authors were emailed once
to request this if it was not published).
• Studies reporting development or validation of a
questionnaire including adherence questions only
relevant to specific illnesses or medications (as pri-
mary care patients have a wide range of conditions).
• Studies reporting a questionnaire focussing on
beliefs about medicines rather than adherence.
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• Studies reporting questionnaires including items
not related to medication adherence (unless medica-
tion adherence items form a separate subscale).
• Studies reporting questionnaires not suitable for
multiple medications (as patients in primary care
often take more than one medication).
• Studies reporting use of a questionnaire with no
description of development or validation or reliabil-
ity testing.
• Studies only reporting validation against another
questionnaire.
• Non peer- reviewed studies.
• Studies which solely include prospective rather
than retrospective questionnaires.
• Diary methods (as these are too intrusive in
patients’ day to day life for routine use).
• Studies where the adherence measure used was not
reproducible.
• Studies where the results were not clearly reported.
• Studies where no statistical comparison was
reported.
Screening and data extraction
One reviewer screened all titles and abstracts in order to
determine whether the full research paper should be
retrieved or whether it was evident it did not meet the
inclusion criteria at this stage. A second reviewer inde-
pendently screened a random 10% sample in order to
check the reliability of the screening (the agreement
level was 91%). The first reviewer reviewed all retrieved
articles to determine whether the article met the inclu-
sion criteria. The second reviewer independently
reviewed a random 10% sample of full text papers to
check reliability (the agreement level was 93%). In addi-
tion, the first and second reviewers discussed all articles
which the first reviewer viewed as being borderline
between inclusion and exclusion. The first reviewer then
extracted data from the included articles. This included
number of items, scale type, time period over which
adherence is measured, measurement of reasons for
non-adherence, description of development of the scale
and the sample size, population and results of validity
and reliability studies.
Results and Discussion
Studies identified
One thousand and twenty six abstracts were screened
and 294 full text articles were obtained. Seventy six
papers met the inclusion criteria [15-91](see Figure 1).
These included 58 measures. The included scales and
properties are shown in additional files 1, 2.
A large amount of recent work on adherence has been
carried out in the area of human immunodeficiency
virus (HIV) and a variety of measures have been used,
many of which have been developed for specific studies.
A large number of these did not meet the inclusion cri-
teria as either the measure used was unavailable or it
contained items which were not generically relevant,
often related to very accurate timing which is of particu-
lar importance to HIV medication but not to medication
for most other conditions. The original Adult AIDS
Clinical Trials Group (AACTG) instrument [92]
(designed to measure adherence to HIV medication)
contains an item related to accurate timing; hence these
papers had to be excluded. However, some studies used
the AACTG without the accurate timing item; therefore
these studies were included.
Pragmatic properties of measures
Limited data were available on the acceptability of the
included measures to respondents. The length of mea-
sures ranged from 1 to 21 items. Where information
regarding completion time is presented (3/58), scales
were all reported to take under 5 minutes to complete.
A variety of formats were used to administer question-
naires including face to face interview, telephone inter-
view, self administration and computer programmes.
Few studies compared different formats. However differ-
ent methods of administering an adherence measure
were compared in two studies [82,89]. Nau [89] found
no difference between administering the VAS (visual
analogue scale) by mail or a non-visual version by tele-
phone, (the latter relied on asking for percentage with-
out the use of the visual scale). Kalichman [82]
compared computer administration of the VAS to tele-
phone administration of the same question without the
visual scale. The adherence assessments obtained by tel-
ephone correlated with those obtained over the compu-
ter (r = 0.7, p < 0.01). However, adherence reported
over the telephone was significantly higher (p < 0.01)
than that reported by computer assessment. As self
report is known to overestimate adherence, these data
may suggest that the adherence question used with the
VAS is less accurate when used without the visual scale.
The majority of the measures were designed for use
with adult patients. However, one measure was used
with adolescents [24] and another was designed for use
with parents to establish adherence rates with their chil-
dren’s medication [90]. No other measures were
reported as having a version which could be completed
by carers of patients.
Many of the measures asked about adherence over a
specified period of time such as a week or a month (43/
58) and would therefore be more suitable for measuring
adherence over a specified time period than those that
did not specify a time period. Measures that did not
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specify a time period (15/58) would not be able to
demonstrate change when repeated over time.
Theoretical properties of measures
There was variation in the detail given about the devel-
opment of scales. Some were described as being devel-
oped in conjunction with a literature review and/or with
input from patients and/or healthcare professionals. Few
were described as being based on an explanatory model.
However, one measure was based on the Transtheoreti-
cal Stages of Change Theory [24,88] and identified the
stage that a patient was at with regard to their medica-
tion taking behaviour, ranging from precontemplation
(not considering taking medication) to maintenance
Number of articles 
retrieved from 
electronic search = 
1608
(Medline=385
Embase=392
CINAHL=165
PschINFO=172
IPA=251
Pharmline=89
HaPI=154)
Number of articles 
after duplicates 
removed = 1026
Number of full 
articles obtained = 
294
Number of 
duplicates 
removed = 582
Number of articles 
excluded after title 
and abstract 
screening = 863
Topic not relevant = 732
Measure contains items not 
related to medication 
adherence = 62
Non peer reviewed = 39
Article not in English = 23
Measure not in English = 4
Measure contains illness 
specific items = 2
Does not contain 
retrospective items = 1
Number of articles 
excluded after 
obtaining full 
article  = 218
Topic not relevant = 83
Measure contains illness 
specific items = 56
Questionnaire not available =
43
Measure contains items not 
related to medication 
adherence = 20
Non peer reviewed = 8
Questionnaire not in English 
= 3
Results unclear = 3
Not suitable for multiple 
medications = 1
Method of assessing non 
Adherence not reproducible 
= 1
Number of articles 
included = 76
Number of reviews 
identified = 10 Full 
articles scanned 
for primary studies
Number of hand 
searched articles  
added = 141
Figure 1 Flow chart of papers identified, screened and evaluated.
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(taking medication as prescribed). It therefore focused
on intentional more than unintentional behaviour. Half
the measures incorporated some reasons for not taking
medication
[15-24,28,29,32-34,36-40,43-45,48,51-53,60-70,74,77,80--
82,85-87] but in the vast majority of cases these reasons
were not developed in conjunction with interviews with
patients and were not necessarily comprehensive. Inten-
tional and unintentional non-adherence were only dis-
tinguished from each other in one measure [35].
Psychometric properties of measures
Data regarding internal and test-retest reliability was
presented for a relatively small number of measures
[28,29,32,36,39,45,53-55,60-65,74,77,80,86,91] (16/58).
Where the data are presented the reliability is generally
acceptable (Cronbach alpha 0.6-0.9, ICC and Kappa >
0.7). The exception is that the Morisky scale is reported
as having low internal reliability in half the papers that
assessed it [36,61,63,65], although the other half
reported acceptable reliability [60,62,64,91].
Validation data were presented in support of the vast
majority of measures (54/58), although this varied in
quality in terms of sampling method, sample size and
the level of statistical information reported. Self report
measures have been correlated with other measures of
adherence: MEMS, pill counts, pharmacy refill data and
clinical measures such as viral load and blood pressure.
For the majority of studies the sampling strategy used
was either not reported or was stated to be a conveni-
ence sample. Sample size varied greatly between studies,
ranging from 22 to 1985. Eleven studies had a very
small sample size (< 50) and were hence unlikely to
identify real differences that may have existed between
measures; possibly leading to the incorrect conclusion
that the test measure was valid.
It is difficult to compare studies due to differences in
sample size, sampling strategy, population and the mea-
sures correlated against. However, some interesting
information can be obtained where two measures have
been compared in the same study. Findings of such stu-
dies have suggested that patients find it easier to esti-
mate general adherence than to report a specific
number of doses missed. Two studies showed that a sin-
gle question asking about a general adherence pattern
over a month had greater validity than asking detailed
questions about the amount of medication missed over
the last few days when correlated with MEMS [50] pill
counts [82] and viral load in HIV patients [82]. How-
ever, these studies do not address the issue of whether
more detailed questions would gather more information
about building a pattern of patients’ medication taking
behaviour and thereby aid the choice of suitable inter-
ventions. In contrast to the above findings [50,82], in
one study the relationship between self reported adher-
ence and viral load reached significance when patients
were asked about the number of doses missed within
the last week but not when they were asked about the
last time they missed a dose over a longer period [73].
These findings suggest that it is question type rather
than time period which improves accuracy and ease of
use. Schneider et al [77] found that patients reported in
cognitive tests that it was easier to respond to questions
with Likert type responses than to questions that asked
about percentages of doses skipped. Lu [50] found that
asking patients to rate their ability to take their medica-
tion was correlated better with MEMS than asking them
how frequently they took them or what percentage of
the time they took them. Whilst social desirability may
be one factor leading to overestimation of adherence,
making questions less judgemental was not found to
increase reporting of non-adherence, suggesting that
other factors such as memory recall, are important [93].
There was little information in the literature regarding
whether dichotomous, Likert or visual analogue scales
are more accurate. In one study [36] a Likert version of
the Morisky measure was created and both this version
and the standard dichotomous version were validated
against pill count. No comparative statistical tests
between the dichotomous and Likert measures were car-
ried out but the descriptive results indicate they per-
formed similarly against the pill count. In another study
a visual analogue scale had higher correlation with psy-
chotropic dose concentration than a likert scale [53]. A
consideration is that the level at which non-adherence
becomes clinically significant varies between medica-
tions. For example a 95% adherence rate is needed for
optimal therapeutic benefit of protease inhibitors to
control HIV [94], a 90% adherence rate is required for
imatinib in the treatment of chronic myeloid leukemia
[95] and for many medications the adherence rate
needed is unknown. Dichotomous categorizations that
rely on arbitrary cut off points such as 80% adherence,
maybe less helpful, compared to a scale, when used by
health care professionals for continuous monitoring of
patients over time in order to increase adherence to a
level that allows optimal therapeutic benefit.
Limitations
The search strategy was designed to identify all adher-
ence/compliance measures described as such by the
authors of instruments and papers. If authors incorrectly
described an adherence instrument as another type of
measure, such as a concordance or persistence measure,
this would not have been identified in the review. In
addition, studies published after the search was com-
pleted would not have been identified.
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Conclusion
Self report has been recommended as the measure most
suitable for clinical practice [7]. A large number of self
report measures have been used to measure adherence
and several measures of adherence have some of the
properties that are required to be used in routine clini-
cal practice, particularly validation against non question-
naire measures. However, there is limited information
about which types of scales are most acceptable and
non intrusive to patients, are the most reliable and
obtain the most accurate information. The scales avail-
able have limited ability to distinguish between inten-
tional and unintentional non-adherence and few scales
allow for the role of carers in medication management.
Currently, the most appropriate instrument will need to
be selected based on the user’s prioritisation of the
properties required e.g. responsiveness to change
(potentially possible with the 43 measures specifying a
time period), established reliability
[28,29,32,36,39,45,53-55,60-65,74,77,80,86,91], provision
of information on causes
[15-24,28,29,32-34,36-40,43-45,48,51-53,60-70,74,77,80--
82,85-87] or suitability for completion by parent [90].
There is a need for the development of a measure
which can be used in the routine continual quality mon-
itoring of adherence services and which meets all the
above criteria.
Additional material
Additional file 1: Properties of adherence scales. A table of all
measures included in the review and their properties including number
of items, scale type, time period over which adherence is measured,
measurement of reasons for non adherence and acceptability.
Additional file 2: Validity and reliability of self reported adherence
scales. A table giving details of validity and reliability studies on included
measures.
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